Top Page
China Resources Pharmaceutical Group Ltd.
(Frankfurt:3320)
China Resources Pharmaceutical Group Ltd. (3320) vs. iShares MSCI Hong Kong ETF (EWH)
China Resources Pharmaceutical Group Ltd. Business Overview & Revenue Model
China Resources Pharmaceutical Group Ltd. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 274.18B | 270.40B | 254.11B | 236.81B | 200.42B | Gross Profit |
| 43.30B | 43.37B | 39.13B | 35.38B | 32.29B | EBIT |
| 12.90B | 12.15B | 10.81B | 9.25B | 8.47B | EBITDA |
| 15.45B | 15.43B | 15.47B | 11.95B | 12.47B | Net Income Common Stockholders |
| 3.57B | 3.85B | 3.50B | 3.08B | 2.78B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 17.48B | 59.27B | 32.52B | 37.32B | 52.34B | Total Assets |
| 274.28B | 271.48B | 241.29B | 248.56B | 209.37B | Total Debt |
| 73.43B | 62.16B | 67.00B | 82.59B | 58.63B | Net Debt |
| 55.95B | 37.51B | 42.88B | 57.26B | 40.91B | Total Liabilities |
| 169.90B | 169.20B | 150.24B | 152.69B | 128.69B | Stockholders Equity |
| 51.34B | 50.60B | 49.56B | 50.98B | 46.47B |
| Cash Flow | Free Cash Flow | |||
| 14.33B | 12.42B | 7.54B | 8.32B | 4.06B | Operating Cash Flow |
| 17.55B | 15.55B | 10.90B | 11.22B | 6.28B | Investing Cash Flow |
| 0.00 | -2.07B | -3.30B | -8.83B | -2.02B | Financing Cash Flow |
| 0.00 | -4.07B | -9.00B | 5.31B | -3.60B |
China Resources Pharmaceutical Group Ltd. Technical Analysis
China Resources Pharmaceutical Group Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$90.04B | 19.58 | 13.20% | 4.42% | -9.60% | -27.18% | |
75 Outperform | $9.77B | 9.87 | 7.27% | 5.62% | 12.03% | 20.45% | |
74 Outperform | $33.20B | 11.77 | 14.56% | 4.98% | -5.37% | 6.28% | |
66 Neutral | $66.58B | 9.10 | 6.08% | 4.50% | 3.27% | 12.87% | |
66 Neutral | $80.12B | 42.22 | 6.14% | 1.39% | 7.63% | -24.23% | |
62 Neutral | HK$33.17B | 9.06 | 3.02% | ― | ― | ||
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% |
China Resources Pharmaceutical Group Ltd. Corporate Events
CR Sanjiu released its unaudited financial results for the first quarter of 2025, reporting a decline in revenue and net profit compared to the same period in 2024. Despite the drop in revenue and profit, the company experienced a significant increase in cash and cash equivalents, indicating strong cash flow management. The financial results highlight a substantial growth in total assets and liabilities, reflecting ongoing expansion efforts. Stakeholders are advised to exercise caution, as these figures are unaudited and may be subject to adjustments.
Tasly Pharmaceuticals, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first quarter of 2025, showing a slight increase in revenue and net profit compared to the same period in 2024. Despite a decrease in cash and cash equivalents, the company’s total assets and owner’s equity remained stable, indicating a steady financial position. Stakeholders are advised to exercise caution as the financials have not been audited and may be subject to adjustments.
KPC Pharmaceuticals, a subsidiary of China Resources Pharmaceutical Group Ltd., reported a decline in revenue and net profit for the first quarter of 2025 compared to the same period in 2024. The unaudited financial results indicate a decrease in cash and cash equivalents, with total assets slightly increasing while liabilities decreased marginally. Stakeholders are advised to exercise caution as the financials are unaudited and may require adjustments.
CR Double-Crane released its unaudited financial results for the first quarter of 2025, reporting a slight decrease in revenue compared to the previous year, but an increase in net profit. The company’s total assets and owner’s equity have grown, while cash and cash equivalents have decreased. Stakeholders are advised to exercise caution as the financials are unaudited and may be subject to adjustments.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first quarter of 2025, showing a slight decrease in revenue but an increase in net profit compared to the previous year. The financial report highlights a net increase in cash and cash equivalents, along with a rise in total assets and owner’s equity, indicating a strong financial position despite the revenue dip. Stakeholders are advised to exercise caution as the financials are unaudited and may be subject to adjustments.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first quarter of 2025, showing a revenue increase to RMB 1.72 billion and a net profit of RMB 425 million. Despite a decrease in cash and cash equivalents, the company maintained strong total assets and owner’s equity, indicating stable financial health. Stakeholders are advised to exercise caution as these figures are unaudited and may be subject to adjustments.
China Resources Pharmaceutical Group Ltd. has announced its upcoming annual general meeting scheduled for May 23, 2025, where shareholders will consider the audited financial statements, declare a final dividend, and re-elect directors. The meeting will also address the re-appointment of KPMG as auditors and authorize the board to fix directors’ remuneration. Additionally, a resolution will be proposed to allow the company to buy back up to 10% of its issued shares, which could impact shareholder value and market perception.
CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the first quarter of 2025, showing an increase in revenue to RMB 535.88 million compared to the previous year. Despite the revenue growth, net profit decreased to RMB 139.29 million, and there was a significant net decrease in cash and cash equivalents, indicating potential liquidity challenges.
China Resources Pharmaceutical Group Ltd. has successfully completed the public issuance of the second tranche of its 2025 Corporate Bonds in the PRC, raising RMB400 million with a coupon rate of 1.93% per annum. The proceeds from this issuance will be used to repay interest-bearing debt, potentially strengthening the company’s financial position and operational capacity.
China Resources Pharmaceutical Group Ltd. has successfully completed the acquisition of a 28% interest in Tasly Pharmaceuticals, making Tasly a non-wholly-owned subsidiary. This strategic acquisition is expected to enhance the company’s market position and expand its operational capabilities in the pharmaceutical industry.
China Resources Pharmaceutical Group Ltd. has announced a final cash dividend of RMB 0.052 per share for the financial year ending December 31, 2024, with an option for shareholders to receive the dividend in Hong Kong dollars at HKD 0.056 per share. This announcement reflects the company’s stable financial performance and commitment to delivering shareholder value, potentially enhancing its market position and investor confidence.
China Resources Pharmaceutical Group Ltd. reported its annual financial results for the year ending December 31, 2024, showing a revenue increase to RMB 257.67 billion from RMB 244.70 billion in 2023. The company’s profit for the year rose to RMB 8.40 billion, with a notable contribution from non-controlling interests. Despite increased selling, distribution, and administrative expenses, the company managed to improve its gross profit, indicating a strong operational performance.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its financial results for the year ended December 31, 2024. The company experienced a slight increase in total assets by 1.66% but faced a decrease in revenue by 2.59%. However, it achieved a notable increase in net profit attributable to shareholders by 9.67%. The board proposed a cash dividend distribution, pending shareholder approval, reflecting a positive outlook despite challenges in revenue growth.
CR Double-Crane, a subsidiary of China Resources Pharmaceutical Group Ltd., reported a decrease in total assets and net profit for the year ending December 31, 2024, compared to the previous year. Despite a slight decline in revenue and net profit, the company saw a significant increase in net profit excluding extraordinary gains or losses, and proposed a cash dividend distribution to shareholders, reflecting a strategic focus on shareholder returns.
CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its financial results for the year ended December 31, 2024. The company experienced a notable decline in revenue by 34.58%, yet saw a significant increase in net profit attributable to shareholders by 67.18%, and a remarkable rise in net profit excluding extraordinary gains or losses by 110.77%. Despite the revenue drop, the company’s profitability improved, indicating effective cost management or operational efficiencies.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., has reported a strong financial performance for the year ended December 31, 2024. The company achieved a notable increase in revenue and net profit, with revenue rising by 25.57% and net profit attributable to shareholders growing by 35.29%. This financial growth highlights Dong-E-E-Jiao’s robust market positioning and operational efficiency, potentially benefiting stakeholders and enhancing the company’s competitive edge in the traditional Chinese medicine sector.
CR Sanjiu, a subsidiary of China Resources Pharmaceutical Group Ltd., reported a notable financial performance for the year ended December 31, 2024. The company achieved an 11.63% increase in revenue and an 18.05% rise in net profit attributable to shareholders. The board has proposed a cash dividend distribution, reflecting strong shareholder returns and a positive outlook for the company’s financial health.
KPC Pharmaceuticals, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its financial results for the year ending December 31, 2024. The company experienced a slight decrease in revenue by 0.34% but saw a significant increase in net profit attributable to shareholders by 19.86%. The board proposed a cash dividend of RMB3.00 per 10 shares, pending approval at the annual general meeting. The financial results highlight KPC’s operational resilience and potential positive impact on shareholder returns, despite a decrease in net assets attributable to shareholders.
China Resources Pharmaceutical Group Ltd. has announced a board meeting scheduled for March 26, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024, and to consider the recommendation of a final dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential returns for shareholders, impacting its market positioning and stakeholder interests.
KPC Pharmaceuticals, partly owned by China Resources Pharmaceutical Group Ltd., has reported its unaudited preliminary financial results for the year ending December 31, 2024. The company showed a slight decrease in total operating revenue by 0.34% compared to the previous year, while experiencing significant growth in operating profit by 17.46% and net profit attributable to shareholders by 19.86%. This performance indicates stronger profitability despite stable revenue figures, which could positively impact China Resources Pharmaceutical Group’s financial outlook.
CR Sanjiu has announced its unaudited preliminary financial results for the year ended December 31, 2024, showing a notable financial performance with a total operating revenue increase of 11.63% and an operating profit rise of 19.28% compared to the previous year. The announcements indicate a strong financial growth trajectory for CR Sanjiu, which may positively impact its positioning in the pharmaceutical industry. The increase in shareholder equity and basic earnings per share suggests improved returns for stakeholders.